Accelerating Precision Medicine for Advanced Cancer Patients My name is Dan Rhodes, CEO of Strata Oncology. This presentation is intended for cancer care providers considering joining us in the Strata Trial. Accelerating Precision Medicine for Advanced Cancer Patients

a precision oncology company broadening patient access & accelerating breakthrough drug approvals At Strata Oncology, we are precision oncology company with dual purpose – broaden patient access today, and at the same time accelerate new drug approvals for cancer patients tomorrow.

The Long Tail of Rare, Targetable Genetic Alterations in Cancer NTRK1-3 MAP2K1 MAPK1 Investigational Drugs Approved Drugs ROS1 Approval for firsrt indication – always are others. Nat Biotechnol. 2013 Nov;31(11):1023-31

CATCH-22 X X X $$ In Precision Oncology Reimbursement Genomic Testing Precision Medicine Trials

Tumor Sequencing + Tx Protocols 100,000 advanced solid tumor patients for screening, with biomarker-positive patients matched to relevant therapeutic protocols The Strata Trial is new kind of clinical trial, unprecedented in scope and size. The Strata Trial is strutured as a screening protocol and a portfolio of affiliated pharma sponsored therapeutic protocols. The trial just began in January of 2017 and seeks to enroll 100,000 advanced cancer patients over the coming years, providing these patients with free tumor sequencing, a test that can cost $3-5,000, as well as for those who match, the opportunity to enroll on a precision medicine clinical trial. Recruiting 100,000 advanced solid tumor and lymphoma patients for screening, with biomarker-positive patients matched to relevant therapeutic protocols 1. No-cost Tumor Sequencing 2. Pharma Trial Portfolio Strata-sponsored observational study provides no-cost tumor sequencing for ALL advanced cancer patients State-of-the-art CLIA NGS testing – StrataNGS™ Best-in-class pharma trials Most compelling early data

No-cost Tumor Sequencing and Clinical Trial Options for 10,000 Men with Metastatic Prostate Cancer Eric Small, MD Professor of Medicine; Urology; and Chief, Division of Hematology/Oncology, UCSF Deputy Director; Prostate Cancer Program Leader, UCSF Helen Diller Family Comprehensive Cancer Center Keith Flaherty, MD Director of Developmental Therapeutics Program, Massachusetts General Professor, Harvard Medical School Principal Investigator, NCI MATCH Co-founder; Chair, Clinical Advisory Board, Strata Oncology Felix Feng, MD Associate Professor of Radiation Oncology; Urology; Vice Chair for Faculty Development and Director of Translational Research, Department of Radiation Oncology, UCSF Scott Tomlins, MD, PhD Assistant Professor, Pathology and Urology, University of Michigan Medical School Michigan Center for Translational Pathology Co-founder; Laboratory Director, Strata Oncology

No-cost Tumor Sequencing and Clinical Trial Options for 10,000 Men with Metastatic Prostate Cancer PROGRAM AIMS Expand access to tumor sequencing for men with metastatic prostate cancer Accelerate enrollment of select precision medicine clinical trials in advanced prostate cancer (rucaparib for BRCA and ATM-mutants) Catalyze new studies for patients harboring other targetable alterations ELIGIBLE PATIENTS Metastatic prostate cancer; hormone-refractory or hormone-sensitive FFPE tumor material available

PROVIDER ORDERS free NGS test No-cost Tumor Sequencing and Clinical Trial Options for 10,000 Men with Metastatic Prostate Cancer INFORM your physician PROVIDER ORDERS free NGS test PROVIDER SENDS specimen to Strata CLIA lab REVIEW NGS test report & trial options

For more information contact us www.stratifyprostate.com stratifyprostatte@strataoncology.com